National Jewish Health and Laboratory Corp of America Holdings have reached an agreement to collaborate in the development and commercialization of molecular diagnostic tests in support of personalized medicine. The collaboration combines National Jewish Health’s strengths in molecular diagnostics and respiratory, immune, and related diseases with LabCorp’s national leadership in personalized medicine and esoteric testing.
"National Jewish’s Advanced Diagnostics Laboratory is the premiere esoteric lab in respiratory, immune, and related diseases," said Gary Smith, PhD, Executive Director of the Advanced Diagnostics Laboratory at National Jewish Health. "This important collaboration with LabCorp will allow us to provide specialized companion diagnostic tools to a much broader audience."
"This agreement further emphasizes LabCorp’s focus on personalized medicine and companion diagnostics," said Dr. Andrew J. Conrad, LabCorp’s Chief Scientist and Global Head of Clinical Trials. "LabCorp is pleased to collaborate with leading institutes, such as National Jewish Health, in order to offer the most advanced testing capabilities."
The parties have established a framework for the discovery, development, and commercialization of diagnostic tests. Financial terms of the agreement were not disclosed.
National Jewish Health is known worldwide for treatment of patients with respiratory, immune, and related disorders, and for groundbreaking medical research.
Source: Businesswire
